

**Axe corticotrope et dépression: état des lieux et perspectives**

Jean-Michel Aubry, Marianne Gex-Fabry

**Bibliographie**

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005;62(6):593-602.
2. Palazidou E. The neurobiology of depression. *Br Med Bull* 2012;101:127-45.
3. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. II. Discrimination of depressed from nondepressed patients. *Arch Gen Psychiatry* 1976;33(9):1051-8.
4. Bardeleben U, Holsboer F. Cortisol response to a combined dexamethasone-human corticotrophin-releasing hormone challenge in patients with depression. *J Neuroendocrinol* 1989;1(6):485-8.
5. Ising M, Kunzel HE, Binder EB, Nickel T, Modell S, Holsboer F. The combined dexamethasone/CRH test as a potential surrogate marker in depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2005;29(6):1085-93.
6. Mokhtari M, Arfken C, Boutros N. The DEX/CRH test for major depression: a potentially useful diagnostic test. *Psychiatry Res* 2013;208(2):131-9.
7. Gatti R, Antonelli G, Prearo M, Spinella P, Cappellin E, De Palo EF. Cortisol assays and diagnostic laboratory procedures in human biological fluids. *Clin Biochem* 2009;42(12):1205-17.
8. Inder WJ, Dimeski G, Russell A. Measurement of salivary cortisol in 2012 - laboratory techniques and clinical indications. *Clin Endocrinol (Oxford)* 2012;77(5):645-51.
9. Dougherty LR, Klein DN, Olino TM, Dyson M, Rose S. Increased waking salivary cortisol and depression risk in preschoolers: the role of maternal history of melancholic depression and early child temperament. *J Child Psychol Psychiatry* 2009;50(12):1495-503.
10. Raul JS, Cirimele V, Ludes B, Kintz P. Detection of physiological concentrations of cortisol and cortisone in human hair. *Clin Biochem* 2004;37(12):1105-11.

11. Staufenbiel SM, Penninx BW, Spijker AT, Elzinga BM, van Rossum EF. Hair cortisol, stress exposure, and mental health in humans: a systematic review. *Psychoneuroendocrinology* 2013;38(8):1220-35.
12. Law R, Hucklebridge F, Thorn L, Evans P, Clow A. State variation in the cortisol awakening response. *Stress* 2013;16(5):483-92.
13. Franz CE, York TP, Eaves LJ, Mendoza SP, Hauger RL, Hellhammer DH, et al. Genetic and environmental influences on cortisol regulation across days and contexts in middle-aged men. *Behav Genet* 2010;40(4):467-79.
14. Velders FP, Kuningas M, Kumari M, Dekker MJ, Uitterlinden AG, Kirschbaum C, et al. Genetics of cortisol secretion and depressive symptoms: a candidate gene and genome wide association approach. *Psychoneuroendocrinology* 2011;36(7):1053-61.
15. Vreeburg SA, Kruijtzter BP, van Pelt J, van Dyck R, DeRijk RH, Hoogendijk WJ, et al. Associations between sociodemographic, sampling and health factors and various salivary cortisol indicators in a large sample without psychopathology. *Psychoneuroendocrinology* 2009;34(8):1109-20.
16. Kudielka BM, Hellhammer DH, Wust S. Why do we respond so differently? Reviewing determinants of human salivary cortisol responses to challenge. *Psychoneuroendocrinology* 2009;34(1):2-18.
17. Lovallo WR, Farag NH, Sorocco KH, Cohoon AJ, Vincent AS. Lifetime adversity leads to blunted stress axis reactivity: studies from the Oklahoma Family Health Patterns Project. *Biol Psychiatry* 2012;71(4):344-9.
18. Knorr U, Vinberg M, Kessing LV, Wetterslev J. Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis. *Psychoneuroendocrinology* 2010;35(9):1275-86.
19. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. *Psychosom Med* 2011;73(2):114-26.
20. Mannie ZN, Harmer CJ, Cowen PJ. Increased waking salivary cortisol levels in young people at familial risk of depression. *Am J Psychiatry* 2007;164(4):617-21.
21. Aubry JM, Jermann F, Gex-Fabry M, Bockhorn L, Van der Linden M, Gervasoni N, et al. The cortisol awakening response in patients remitted from depression. *J Psychiatr Res* 2010;44(16):1199-204.
22. Schule C. Neuroendocrinological mechanisms of actions of antidepressant drugs. *J Neuroendocrinol* 2007;19(3):213-26.
23. McKay MS, Zakzanis KK. The impact of treatment on HPA axis activity in unipolar major depression. *J Psychiatr Res* 2010;44(3):183-92.

24. Matousek RH, Dobkin PL, Pruessner J. Cortisol as a marker for improvement in mindfulness-based stress reduction. *Complement Ther Clin Pract* 2010;16(1):13-9.
25. Gex-Fabry M, Jermann F, Kosel M, Rossier MF, Van der Linden M, Bertschy G, et al. Salivary cortisol profiles in patients remitted from recurrent depression: one-year follow-up of a mindfulness-based cognitive therapy trial. *J Psychiatr Res* 2012;46(1):80-6.
26. Brouwer JP, Appelhof BC, van Rossum EF, Koper JW, Fliers E, Huyser J, et al. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. *Psychoneuroendocrinology* 2006;31(10):1154-63.
27. Bockting CL, Lok A, Visser I, Assies J, Koeter MW, Schene AH. Lower cortisol levels predict recurrence in remitted patients with recurrent depression: a 5.5 year prospective study. *Psychiatry Res* 2012;200(2-3):281-7.
28. Vreeburg SA, Hoogendijk WJ, Derijk RH, van Dyck R, Smit JH, Zitman FG, et al. Salivary cortisol levels and the 2-year course of depressive and anxiety disorders. *Psychoneuroendocrinology* 2013;38(9):1494-502.